Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG)

Background: Evaluation of the potential efficacy and safety of combination therapies for advanced soft tissue sarcomas (STS) has increased substantially after approval of trabectedin and pazopanib. Trabectedin’s introduction in Europe in 2007 depended mainly on its activity in so-called L-sarcomas (...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mar Drugs
Glavni autori: Kasper, Bernd, Reichardt, Peter, Pink, Daniel, Sommer, Michaela, Mathew, Monika, Rauch, Geraldine, Hohenberger, Peter
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4306943/
https://ncbi.nlm.nih.gov/pubmed/25591040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/md13010379
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items